読み込み中
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
前日終値
$0.5803
+$0.0361 · +6.63%
日中の時刻はETです。市場データは遅延する場合があります。
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
日中レンジ
現在 $0.5803
52週レンジ
現在 $0.5803
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
39
弱気
リスク
85
極めて高いリスク
モメンタム
47
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
日中レンジ
現在 $0.5803
52週レンジ
現在 $0.5803
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 843.6万 USD | 846.8万 USD | 868.7万 USD | 871.3万 USD | 402.5万 USD |
| 粗利益 | −843.6万 USD | −846.8万 USD | −868.7万 USD | −871.3万 USD | −402.5万 USD |
| 研究開発 | 6860.7万 USD | 8674.2万 USD | 9803.8万 USD | 9453.7万 USD | 5439.3万 USD |
| 販売・一般管理 | 2472.4万 USD | 2073.8万 USD | 2446.8万 USD | 2237.1万 USD | 1438.8万 USD |
| 営業費用 | 8489.5万 USD | 1.07億 USD | 1.23億 USD | 1.17億 USD | 6878.1万 USD |
| 受取利息 | 268.2万 USD | 473.7万 USD | 705.6万 USD | 195.4万 USD | 10.8万 USD |
| 減価償却費と償却費 | 843.6万 USD | 846.8万 USD | 868.7万 USD | 646.7万 USD | 296.1万 USD |
| 営業利益 | −9333.1万 USD | −1.16億 USD | −1.31億 USD | −1.26億 USD | −7280.6万 USD |
| 純利益 | −9059.7万 USD | −1.11億 USD | −1.24億 USD | −1.24億 USD | −7272.1万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$2.33
上昇余地（301.52%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
